Volume 3, Issue 4 (Summer 2011)                   Iranian Journal of Blood and Cancer 2011, 3(4): 51-53 | Back to browse issues page

XML Print


Abstract:   (20260 Views)
Background: Hemoglobin S arises is the result of a point mutation (A-T) in the sixth codon on the -globin gene on chromosome 11 causing sickle cell anemia. The presence of fetal hemoglobin in infancy plays a relatively protective role for vaso-occlusive symptoms that are the major contributor for the morbidity and mortality among patients with sickle cell anemia. hydroxyurea, an s-phase-specific and non-DNA-hypomethylating chemotherapeutic agent is capable of inducing HbF synthesis. Materials and Methods: We reviewed the records of 28 sickle cell anemia patients, aged 4-52 years, treated with hydroxyurea to study the drug’s side effects. Results: In our study, the most common adverse effect was dermatologic complication which occurred in 15 patients (53.5%). The gastrointestinal side effects were nausea, vomiting, abdominal pain and anorexia occurring in 3 patients 10.7%. The neurologic adverse effects were uncommon and occurred in 4 patients (14.3%). Conclusion: Side effects of hydroxyurea were common but mild to moderate, benign and transient. Starting a low dose of hydroxyurea (10 mg/kg per day) and increasing the dose slowly in pediatric and adult patients with sickle cell anemia can be tolerated well, without serious side effects. Keywords: Side effect, hydroxyurea, sickle cell, anemia.
Full-Text [PDF 420 kb]   (2280 Downloads)    
: Original Article | Subject: Pediatric Hematology & Oncology
Received: 2013/01/26 | Accepted: 2015/01/3 | Published: 2015/01/3

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.